eligibility_summary
Eligibility: CD20+ B‑cell lymphoma (DLBCL and listed indolent/aggressive subtypes), R/R after ≥2 lines, ASCT allowed, measurable disease, therapy washouts met, adequate organs (EF≥45%, O2 sat>90%), ECOG 0–2, weight ≥45 kg. Exclude: CLL/SLL, mantle, Burkitt, EBV+ DLBCL, B‑ALL, Richter’s, CNS disease, prior allo‑HSCT, significant cardiac/pulmonary disease, active HBV/HCV/HIV/COVID, prior CD20 CAR‑T/bi‑specific, rituximab ≤14 d, anticoagulants. LDC: no bridging ≤10 d, no infection/fever, no high‑dose steroids ≤24 h, no major surgery ≤28 d.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial NCT06248086 (terminated): First‑in‑human, phase 1, open‑label study of ASP2802 plus MA‑20 in relapsed/refractory CD20+ B‑cell lymphomas. Interventions/mechanisms: ASP2802 is an autologous, genetically engineered convertibleCAR‑T cell therapy (cellular immunotherapy) that expresses an inert NKG2D‑based receptor, it requires an adaptor to engage tumor. MA‑20 (ASP101G) is a MicAbody adaptor protein/bispecific antibody that binds CD20 on B cells and carries an orthogonal NKG2D ligand to dock and activate the convertibleCAR‑T, enabling titratable, on/off targeting via repeated “booster” doses. Cells/pathways targeted: malignant CD20‑positive B cells, CD20 antigen, engineered T cells via CAR signaling (immune synapse formation, cytotoxic T‑cell activation through CAR/CD3ζ costimulation), adaptor‑mediated NKG2D‑orthogonal ligand interface controlling T‑cell engagement.